Media ReleasesImmutep

View All Immutep News


Immutep Announces First Patient Dosed in TACTI-002 Phase II Trial

• The First Patient has been dosed at “START Madrid- FJD” in Spain

• Clinical trial sites are active and more will be activated and commence recruitment in coming months

SYDNEY, AUSTRALIA – March 6, 2019 – Immutep Limited (ASX:IMM; NASDAQ:IMMP) ("Immutep” or “the Company”), announces the first patient has been dosed with the combination of Keytruda® and efti for TACTI-002, a Phase II clinical study.

TACTI-002 (Two ACTive Immunotherapies) is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada). The study will evaluate the combination of Immutep’s lead product candidate eftilagimod alpha (“efti” or “IMP321”) with MSD’s KEYTRUDA® (or pembrolizumab, a PD-1 blocking antibody) in up to 109 patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line. The study will take place in up to 13 study centres across the U.S., Europe and Australia.


For further information please download PDF attached:
Download this document